Patents Assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
  • Patent number: 11913076
    Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer, including certain gene expression profiles that differentiate between subjects of African and Caucasian descent and other gene expression profiles that are common to subjects of both African and Caucasian descent. The gene expression profiles can be measured at the nucleic acid or protein level and used to stratify prostate cancer based on ethnicity. The gene expression profiles can also be used to identify a subject for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and an array comprising probes for detecting the unique gene expression profiles associated with prostate cancer in subjects of African and/or Caucasian descent.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: February 27, 2024
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Indu Kohaar
  • Patent number: 11884718
    Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: January 30, 2024
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The Army
    Inventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
  • Patent number: 11865111
    Abstract: Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: January 9, 2024
    Assignees: Southwest Research Institute, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Jonathan A. Bohmann, Nadean M. Gutierrez, Joseph A. McDonough, Robert Francis Campbell, Michael Gordon Joyce, Rekha Panchal, Rajeshwer Sankhala, Allen Duplantier
  • Patent number: 11800983
    Abstract: Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 31, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Jason D. Riley, Franck Amyot, Amir H. Gandjbakhche, James G. Smirniotopoulos, Eric Wassermann
  • Publication number: 20230285539
    Abstract: The present disclosure relates to the field of vaccines and binding molecules, as well as preparations and methods of their use in the treatment and/or prevention of disease. Described are vaccines and binding molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections, in particular, ?-coronaviruses such as SARS- CoV-2, the causative agent of COVID-19, as well as SARS-CoV-1 and other coronaviruses.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 14, 2023
    Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States, as Represented by the Secretary of the Army
    Inventors: Michael Gordon JOYCE, Kayvon MODJARRAD
  • Publication number: 20230280349
    Abstract: In aspects, the disclosure provides a method of differentiating a malignant tumor from a non-malignant tumor in a mammal having a tumor comprising determining in a sample from the mammal the level of one or more of: (1) transthyretin (TTR) RNA or protein, (2) dual oxidase 2 (DUOX2) RNA or protein, and (3) G-protein coupled receptor 179 (GPR179) RNA or protein.
    Type: Application
    Filed: March 1, 2023
    Publication date: September 7, 2023
    Applicants: The University of Chicago, Inova Health System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Ayman Al-Hendy, Hiba Alkelani, Thomas Patrick Conrads, George Larry Maxwell, Nicholas William Bateman, Waleed Barakat
  • Patent number: 11744829
    Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: September 5, 2023
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Maria F. Braga, Vassiliki Aroniadou-Anderjaska
  • Publication number: 20230266418
    Abstract: Diffusion sensitizing gradient pulse pairs are prescribed in a manner to mitigate effects of concomitant gradient artifacts. Measured MR signals generated by applying a plurality of diffusion sensitizing gradient matrices are obtained and processed to determine a second order mean diffusion tensor and a fourth order covariance tensor. Quantities derived from these tensors are measured and mapped within an imaging volume which describe features of diffusion anisotropy and heterogeneity within each imaging voxel.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 24, 2023
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Magdoom Mohamed Kulam Najmudeen, Peter J. Basser, Michal E. Komlosh
  • Publication number: 20230241196
    Abstract: Methods are disclosed for inducing an immune response to Neisseria gonorrhoeae in a mammalian subject. These methods include administering to the mammalian subject an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide, thereby inducing the immune response. Also disclosed are immunogenic compositions including an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide.
    Type: Application
    Filed: January 26, 2021
    Publication date: August 3, 2023
    Applicants: Oregon State University, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Aleksandra E. Sikora, Ryszard A. Zielke, Ann E. Jerse
  • Patent number: 11648239
    Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: May 16, 2023
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
  • Patent number: 11600373
    Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: March 7, 2023
    Assignees: MESO SCALE TECHNOLOGIES, LLC., THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: William F. Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
  • Patent number: 11583578
    Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 21, 2023
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government Of The United States, As Represented By The Secretary Of The Army
    Inventors: Sheetij Dutta, Zoltan Beck, Carl Alving, Gary Matyas
  • Patent number: 11572389
    Abstract: Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 7, 2023
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Xinle Cui, Clifford M. Snapper
  • Patent number: 11559579
    Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 24, 2023
    Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
  • Publication number: 20230018537
    Abstract: The present disclosure describes methods and systems for predicting severe disease in an individual with sepsis or at risk of developing sepsis, in order to prevent severe disease in an individual with sepsis. The present disclosure also describes methods of using topological data analysis and/or clustering to stratify sepsis based on biomolecular signatures and identify distinct phenotypes in sepsis patients.
    Type: Application
    Filed: December 24, 2020
    Publication date: January 19, 2023
    Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Joost Brandsma, Danielle Clark, Rittal Mehta, Deborah Striegel
  • Patent number: 11492414
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 8, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
  • Publication number: 20220326257
    Abstract: Described herein are deiminated proteins that are deiminated in response to oxygen-deprivation brain injury (ODBI) and/or oxygen-deprivation causing injury (ODCI). Also described are related methods and devices for detecting, diagnosing, and monitoring ODBI or ODCI, and methods for treating ODBI or ODCI.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 13, 2022
    Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventor: Gregory P. MUELLER
  • Patent number: 11426069
    Abstract: Provided are methods and system for assessing a human subject's neurological and/or psychological status. The methods entail displaying visual tests to a human subject, wherein each of the visual tests includes a visual target signal, optionally with visual cue signals, for eliciting visual and, optionally, body part, movements by the subject. Following the display, the movements are then detected. The latency and/or correctness of such movements can then be used to assess the subject's neurological and/or psychological status. Also provided are methods and systems for assessing performance validity.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: August 30, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Mark L. Ettenhofer, David Barry
  • Publication number: 20220257266
    Abstract: An intracranial access device includes a housing having an operator-facing side and a patient-facing side and an opening therethrough extending from the operator-facing side to the patient-facing side. The device further includes at least one fastener configured to secure the device to a cranium of a patient. The device further includes a drill mounted to a surface of the housing and a cauterizer. The device may further include a number of sensors arranged on the patient-facing side of the housing and configured to identify a hemorrhage location.
    Type: Application
    Filed: July 16, 2020
    Publication date: August 18, 2022
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Johns Hopkins University
    Inventors: David L. Brody, David Blodgett, Carissa Rodriguez, Timothy Sleasman, Michael J. Fitch, Adam Cohen, Max R. Basescu, Kevin C. Wolfe, Jared M. Wormley
  • Patent number: 11345653
    Abstract: The invention relates to compounds, compositions and methods for activating, reactivating, reversing or preventing the deactivation of cholinesterases, such as acetylcholinesterase and butyrylcholinesterase.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 31, 2022
    Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., The Government of the United States as Represented by the Secretary of the Army
    Inventors: Ilja Khavrutskii, Sven Anders Wallqvist